Showing 8671-8680 of 9129 results for "".
- Survey Reveals Attitudes About Lip Healthhttps://practicaldermatology.com/news/survey-reveals-attitudes-about-lip-health/2458937/The majority of Americans suffer from dry and chapped lips, and 1 in 4 say that when their lips are chapped and flaky they don’t look attractive. Furthermore, close to 1 in 5 say their self-confidence goes down when their lips are chapped and flaky and, some even
- arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditionshttps://practicaldermatology.com/news/argen-x-and-leo-pharma-enter-into-alliance-to-develop-antibody-based-treatments-for-skin-conditions/2458940/arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma entered into an alliance in which they will collaborate to develop antibody-based solutions for the treatment
- AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/abbvie-receives-fda-orphan-drug-designation-for-humira-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa/2458945/AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie's su
- ASDS Releases Consensus Recommendations on Basal Cell Carcinomahttps://practicaldermatology.com/news/asds-releases-consensus-recommendations-on-basal-cell-carcinoma/2458947/An expert group of dermatologic surgeons appointed by the American Society for Dermatologic Surgery (ASDS) Board of Directors has developed the first-ever consensus recommendations on the treatment and management of basal cell carcinoma (BCC). According to the ASDS, the document is intend
- Skin Cancer Screening Initiative from AAD: ‘Who's Got Your Back?'https://practicaldermatology.com/news/skin-cancer-screening-initiative-from-aad-whos-got-your-back/2458952/In recognition of Melanoma/Skin Cancer Detection and Prevention Month in May and Melanoma Monday, observed on May 4 this year, the American Academy of Dermatology (AAD) asks the public to consider “Who’s Got Your Back?” when it comes to applying sunscreen and examining skin for
- ASDS Honors Legacy of Dr. Fredric Brandthttps://practicaldermatology.com/news/asds-honors-legacy-of-dr-fredric-brandt/2458958/The American Society for Dermatologic Surgery is paying tribute to the late cosmetic dermatologist Fredric S. Brandt, MD by setting up two memorial funds in his honor. Dr. Brandt, an ASDS member since 1982, died earlier this month at age 65 at his Florida home. The ASDS said the funds are
- AcneCareMD Website Launcheshttps://practicaldermatology.com/news/acnecaremd-website-launches/2458957/Jamie Altman, MD, owner and president of Aesthetic Dermatology Associates, PC, in Media and Paoli, PA, launched AcneCareMD.com, a secure telemedicine website to provide acne care to patients across Pennsylvania via
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- Senate Passes Bill to Repeal SGRhttps://practicaldermatology.com/news/senate-passes-bill-to-repeal-sgr/2458967/This week saw the end of the sustainable growth rate (SGR), with the US Senate passing the Medicare Access and CHIP Reauthorization Act (H.R.2) in a 92-8 vote and President Obama signing it into law. The bill, which the Hous